Inhibitors of gankyrin are expected to have a negative effect on tumour formation and growth (indeed, inhibition of gankyrin expression by siRNA has been shown to have such effects both in vitro and in vivo4, 6, 7), and gankyrin is therefore regarded as a promising target for potential anticancer therapeutic agents8, 9. Here, PSMD10 is linked to neoplasm.